Contact dermatitis due to topical spironolactone.
Fernandez-Vozmediano
J M
JM
Dermatology Department, Faculty of Medicine, University of Cadiz, University Hospital, Spain.
Gil-Tocados
G
G
Manrique-Plaza
A
A
Romero-Cabrera
M A
MA
Picazo-Sanchez
J
J
Nieto-Montesinos
I
I
D000287:Administration, Topical; D000328:Adult; D000505:Alopecia / Q000188:drug therapy; D017449:Dermatitis, Allergic Contact / Q000209:etiology*; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D012536:Scalp Dermatoses / Q000139:chemically induced*; D013148:Spironolactone / Q000008:administration & dosage / Q000009:adverse effects*
D013148:Spironolactone